Literature DB >> 7299540

Chelation therapy in beta-thalassemia major. III. The role of splenectomy in achieving iron balance.

J H Graziano, S Piomelli, M Hilgartner, P Giardina, M Karpatkin, M Andrew, N LoIacono, C Seaman.   

Abstract

Transfusion requirements for 1978 were compiled for 79 patients with thalassemia major (ages 1 to 29 years) who were maintained at hemoglobin concentrations of greater than 10 gm/dl. In 46 patients with intact spleens, the mean transfusion requirement was 258 ml/kg/year, and there was a clear increase with age. The transfusion history prior to 1978 had no influence on the increase of transfusion requirement with age. In contrast, in 33 splenectomized patients, the mean transfusion requirement was 203 ml/kg/year and it did not increase with age. Urinary iron excretion in response to deferoxamine increased with age, with no obvious difference between splenectomized and nonsplenectomized patients. The ability to achieve iron balance with a daily dose of 20 mg/kg of deferoxamine was a function of the transfusion requirement splenectomized patients with lower blood requirements generally achieved negative iron balance, whereas nonsplenectomized patients did not. We conclude that the spleen should be removed when the transfusion requirement exceeds 250 ml/kg/year, which usually occurs between 6 and 8 years of age. In young patients with intact spleens, a higher dose of deferoxamine may be use in order to prevent hemosiderosis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7299540     DOI: 10.1016/s0022-3476(81)80386-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  6 in total

1.  Immunological abnormalities in thalassaemia major. I. A transfusion-related increase in circulating cytoplasmic immunoglobulin-positive cells.

Authors:  A N Akbar; P J Giardina; M W Hilgartner; R W Grady
Journal:  Clin Exp Immunol       Date:  1985-11       Impact factor: 4.330

2.  Red cell alloimmunization in a diverse population of transfused patients with thalassaemia.

Authors:  Alexis A Thompson; Melody J Cunningham; Sylvia T Singer; Ellis J Neufeld; Elliott Vichinsky; Robert Yamashita; Patricia Giardina; Hae-Young Kim; Felicia Trachtenberg; Janet L Kwiatkowski
Journal:  Br J Haematol       Date:  2011-02-17       Impact factor: 6.998

Review 3.  Surgical and anaesthetic outcomes of paediatric splenectomies at a tertiary care institution in South India: a retrospective cohort.

Authors:  Aureen Ruby DCunha; Ekta Rai; Tarun John K Jacob; Anup J Devasia; Grace Rebekah
Journal:  Pediatr Surg Int       Date:  2022-07-29       Impact factor: 2.003

4.  Partial splenectomy in homozygous beta thalassaemia.

Authors:  M de Montalembert; R Girot; Y Revillon; D Jan; L Adjrad; F Z Ardjoun; M Belhani; Y Najean
Journal:  Arch Dis Child       Date:  1990-03       Impact factor: 3.791

5.  Modulation of the defective natural killer activity seen in thalassaemia major with desferrioxamine and alpha-interferon.

Authors:  A N Akbar; P A Fitzgerald-Bocarsly; P J Giardina; M W Hilgartner; R W Grady
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

6.  Achievement of Pre- and Post-Transfusion Hemoglobin Levels in Adult Transfusion-Dependent Beta Thalassemia: Associated Factors and Relationship to Reduction of Spleen Enlargement.

Authors:  Tubagus Djumhana Atmakusuma; Edison Yantje Parulian Saragih; Wulyo Rajabto
Journal:  Int J Gen Med       Date:  2021-11-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.